

12222 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Supply Management Committee. As soon as the DOD representative is selected, a meeting date will be established. Mr. Sorett will coordinate the meeting arrangements. It was agreed that the Task Group would select its own chairman from its group.

4. Future time schedules for accomplishment of specific tasks and for reporting of the implementation of Recommendation 3. In order to accomplish this item, the Committee agreed to give further study to Recommendation 3(a) and (b) to complete implementation.

5. Consideration of FDA/Committee discussions regarding implementation of Recommendation 4.

Mr. Sorett called to the Committee's attention two communications from (1) Mr. W. Vance Breyfogle, Executive Director, Medical-Surgical Manufacturers Association, and (2) Mr. C. Joseph Stetler, President, Pharmaceutical Manufacturers Association, both of Washington, D.C., expressing an interest in the work of this Committee. (Copies of letters were distributed.)

Mr. Thomas W. Brown, Director, Compliance Coordination and Policy Staff, OACC, FDA, was presented. Mr. Brown informed the Committee that the Steering Committee-Government-Wide Quality Assurance Program for Drugs and Medical Items, proposed to prepare several strategy documents and action plans to implement this recommendation. He noted that representation